Government Cancer Tech Available for Biotech License
Published Date: 7/16/2026
Notice
Summary
The National Cancer Institute has invented a cool new way to grow special immune cells called TCR-T cells that can better fight cancer. This method helps companies make more powerful, targeted cell therapies by boosting the right cells and cutting out the extras. If you’re in biotech or cancer treatment, this is your chance to license a game-changing tool that could speed up cancer cures and bring new treatments to patients faster.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
NCI TCR-T Method Available to License
The National Cancer Institute is offering a government-owned method (NIH Reference Number E-143-2024-0) for license to companies interested in commercializing TCR-engineered T cells. Interested parties can contact Andrew Burke, Ph.D., at [email protected] or 240-276-5484 to pursue licensing for a Clinical Phase II technology.
Manufacturing Method Yields Highly Enriched Cells
The method uses irradiated feeder cells and an anti-mouse TCR beta constant region antibody (for example, H57) in place of OKT3 to selectively expand murine-human hybrid TCR-expressing T cells under GMP conditions. This process produces a cell product highly enriched for the engineered cells, which improves manufacturing quality for companies making personalized adoptive cell therapies.
Potential Improved Therapeutic Benefit for Patients
NCI reports that T cells produced with this method show increased persistence, improved surface expression of the therapeutic TCR alpha/beta, and reduced risk of mis-pairing with endogenous chains. These features are described as increasing therapeutic benefit for adoptive cell transfer in oncology applications.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-17687, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in October 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, ensuring fair and confidential decisions. Scientists applying for grants in genetics, molecular sciences, oral health, and cancer research are the ones affected, with no direct cost changes announced.
2026-17438, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings in late September 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers applying for funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
Previous / Next Documents
Previous: 2026-14345, United States of America, et al. v. RealPage, Inc., et al.; Proposed Final Judgment and Competitive Impact Statement
The U.S. government is stopping Willow Bridge Property Company from using RealPage’s pricing software that shares sensitive info with other landlords. This change will help keep rental prices fair and competitive. Willow Bridge must also follow new rules and work with the government, with public comments open for 60 days.
Next: 2026-14347, Government Owned Invention Available for License: Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients With Chronic Viral Infection(s)
The National Cancer Institute has created a new way to make special immune cells called PILs that can fight chronic HPV infections causing painful growths in the throat and genital areas. This new cell therapy could reduce the need for repeated surgeries, improving patients’ lives and cutting healthcare costs. Researchers are now looking for partners to help develop and license this promising treatment soon.